{
    "organizations": [],
    "uuid": "51f7a2fb0b286433b65e4a872576c94c7c8fcc65",
    "author": "",
    "url": "https://www.reuters.com/article/brief-janssen-submits-marketing-authoris/brief-janssen-submits-marketing-authorisation-application-to-ema-for-apalutamide-idUSFWN1PZ0CP",
    "ord_in_thread": 0,
    "title": "BRIEF-‍Janssen Submits Marketing Authorisation Application To EMA For Apalutamide",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 46 AM / in 5 minutes BRIEF-‍Janssen Submits Marketing Authorisation Application To EMA For Apalutamide Reuters Staff 1 Min Read \nFeb 9 (Reuters) - \n* ‍JANSSEN SUBMITS MARKETING AUTHORISATION APPLICATION FOR APALUTAMIDE TO TREAT PATIENTS WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER​ \n* ‍JANSSEN PHARMACEUTICAL - SUBMITTED MARKETING AUTHORISATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) FOR APALUTAMIDE​ Source text for Eikon:",
    "published": "2018-02-09T10:43:00.000+02:00",
    "crawled": "2018-02-09T11:02:44.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "submits",
        "marketing",
        "authorisation",
        "application",
        "ema",
        "apalutamide",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "submits",
        "marketing",
        "authorisation",
        "application",
        "apalutamide",
        "treat",
        "patient",
        "prostate",
        "pharmaceutical",
        "submitted",
        "marketing",
        "authorisation",
        "application",
        "european",
        "medicine",
        "agency",
        "ema",
        "source",
        "text",
        "eikon"
    ]
}